Increased Risk of Cardiovascular Events Under the Treatments with Janus Kinase Inhibitors Versus Biological Disease-modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis: a Retrospective Longitudinal Population-based Study Using The...

Overview

Journal RMD Open

Publisher BMJ Publishing Group

Specialty Rheumatology

Date 2024 Jun 17

PMID 38886005

Authors

Ryoko Sakai

Eiichi Tanaka

Eisuke Inoue

Masayoshi Harigai

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare the risk of cardiovascular events among Janus kinase inhibitors (JAKIs), biological disease-modifying antirheumatic drugs (bDMARDs) (tumour necrosis factor inhibitors (TNFIs) and non-TNFIs) and methotrexate (MTX) in Japanese patients with rheumatoid arthritis (RA).

Methods: Using Japanese claims data, patients with RA were enrolled in this study if they had at least one ICD-10 code (M05 or M06), were new users of JAKIs, bDMARDs or MTX between July 2013 and July 2020 and being 18 years old or older. The incidence rate (IR), IR ratio and adjusted hazard ratio (aHR (95% CI)) of cardiovascular events including venous thromboembolism, arterial thrombosis, acute myocardial infarction and stroke were calculated. A time-dependent Cox regression model adjusted for patient characteristics at baseline was used to calculate aHR.

Results: In 53 448 cases, IRs/1000 patient-years of the overall cardiovascular events were 10.1, 6.8, 5.4, 9.1 and 11.3 under the treatments with JAKIs, bDMARDs, TNFIs, non-TNFIs and MTX, respectively. The adjusted HRs of JAKIs for overall cardiovascular events were 1.7 (1.1 to 2.5) versus TNFIs without MTX and 1.7 (1.1 to 2.7) versus TNFIs with MTX.

Conclusions: Among patients with RA, individuals using JAKIs had a significantly higher risk of overall cardiovascular events than TNFIs users, which was attributed to the difference in the risk between JAKIs and TNFIs versus MTX. These data should be interpreted with caution because of the limitations associated with the claims database.

Citing Articles

Treating Cardiovascular Disease in the Inflammatory Setting of Rheumatoid Arthritis: An Ongoing Challenge.

Godbole S, Solomon J, Johnson M, Srivastava A, Carsons S, Belilos E Biomedicines. 2024; 12(7).

PMID: 39062180 PMC: 11275112. DOI: 10.3390/biomedicines12071608.

References

Taylor P, Weinblatt M, Burmester G, Rooney T, Witt S, Walls C . Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis. Arthritis Rheumatol. 2019; 71(7):1042-1055. PMC: 6618316. DOI: 10.1002/art.40841. View

Salinas C, Louder A, Polinski J, Zhang T, Bower H, Phillips S . Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases. Rheumatol Ther. 2022; 10(1):201-223. PMC: 9660195. DOI: 10.1007/s40744-022-00505-1. View

Liang H, Danwada R, Guo D, Curtis J, Kilpatrick R, Hendrickson B . Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019; 5(2):e001013. PMC: 6803007. DOI: 10.1136/rmdopen-2019-001013. View

Meissner Y, Richter A, Manger B, Tony H, Wilden E, Listing J . Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort. Ann Rheum Dis. 2017; 76(9):1583-1590. PMC: 5561376. DOI: 10.1136/annrheumdis-2017-211209. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Sepriano A, Kerschbaumer A, Bergstra S, Smolen J, van der Heijde D, Caporali R . Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2022; 82(1):107-118. DOI: 10.1136/ard-2022-223357. View

Karpouzas G, Ormseth S, Hernandez E, Budoff M . Biologics May Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Coronary Plaque Formation and Stabilizing High-Risk Lesions. Arthritis Rheumatol. 2020; 72(9):1467-1475. DOI: 10.1002/art.41293. View

Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E . Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis. 2022; 82(2):182-188. DOI: 10.1136/ard-2022-222824. View

Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J . Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2022; 82(2):189-197. PMC: 9887398. DOI: 10.1136/ard-2022-223050. View

10.

Deyab G, Hokstad I, Whist J, Smastuen M, Agewall S, Lyberg T . Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res Ther. 2017; 19(1):232. PMC: 5646156. DOI: 10.1186/s13075-017-1439-1. View

11.

Kim S, Solomon D, Liu J, Franklin J, Glynn R, Schneeweiss S . Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2014; 128(5):539.e7-17. PMC: 4414700. DOI: 10.1016/j.amjmed.2014.11.025. View

12.

Heit J . Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015; 12(8):464-74. PMC: 4624298. DOI: 10.1038/nrcardio.2015.83. View

13.

Barnabe C, Martin B, Ghali W . Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010; 63(4):522-9. DOI: 10.1002/acr.20371. View

14.

Takeuchi T, Tanaka Y, Rokuda M, Izutsu H, Kaneko Y, Fukuda M . A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Mod Rheumatol. 2020; 31(3):543-555. DOI: 10.1080/14397595.2020.1836789. View

15.

Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K . Anticoagulation Therapy for Venous Thromboembolism in the Real World　- From the COMMAND VTE Registry. Circ J. 2018; 82(5):1262-1270. DOI: 10.1253/circj.CJ-17-1128. View

16.

Meissner Y, Schafer M, Albrecht K, Kekow J, Zinke S, Tony H . Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open. 2023; 9(4). PMC: 10603345. DOI: 10.1136/rmdopen-2023-003489. View

17.

Harigai M, Takeuchi T, Smolen J, Winthrop K, Nishikawa A, Rooney T . Safety profile of baricitinib in Japanese patients with active rheumatoid arthritis with over 1.6 years median time in treatment: An integrated analysis of Phases 2 and 3 trials. Mod Rheumatol. 2019; 30(1):36-43. DOI: 10.1080/14397595.2019.1583711. View

18.

Mori S, Ogata F, Tsunoda R . Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review. Clin Rheumatol. 2021; 40(11):4457-4471. PMC: 8458792. DOI: 10.1007/s10067-021-05911-4. View

19.

Ytterberg S, Bhatt D, Mikuls T, Koch G, Fleischmann R, Rivas J . Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386(4):316-326. DOI: 10.1056/NEJMoa2109927. View

20.

Smolen J, Landewe R, Bergstra S, Kerschbaumer A, Sepriano A, Aletaha D . EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2022; 82(1):3-18. DOI: 10.1136/ard-2022-223356. View